NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant
issuer and to the FCA in Microsoft Word format if
possible)i
|
||||||
|
||||||
1a. Identity of the issuer or the underlying issuer of existing
shares to which voting rights are attachedii:
|
GlaxoSmithKline
plc
|
|||||
1b. Please indicate if the issuer is a non-UK issuer
(please mark with an “X”
if appropriate)
|
||||||
Non-UK issuer
|
|
|||||
2. Reason for the notification (please mark the appropriate
box or boxes with an “X”)
|
||||||
An
acquisition or disposal of voting rights
|
X
|
|||||
An
acquisition or disposal of financial instruments
|
|
|||||
An
event changing the breakdown of voting rights
|
|
|||||
Other
(please specify)iii:
|
|
|||||
3. Details of person subject to the notification
obligationiv
|
||||||
Name
|
The Capital Group Companies, Inc. (“CGC”)
|
|||||
City
and country of registered office (if applicable)
|
Los
Angeles, CA 90071, USA
|
|||||
4. Full name of shareholder(s) (if different from
3.)v
|
||||||
Name
|
|
|||||
City
and country of registered office (if applicable)
|
|
|||||
5. Date on which the threshold was crossed or
reachedvi:
|
13 May
2020
|
|||||
6. Date on which issuer notified
(DD/MM/YYYY):
|
15 May
2020
|
|||||
7. Total positions of person(s) subject to the notification
obligation
|
||||||
|
% of
voting rights attached to shares (total of 8. A)
|
% of
voting rights through financial instruments (total of 8.B 1 + 8.B
2)
|
Total
of both in % (8.A + 8.B)
|
Total
number of voting rights of issuervii
|
||
Resulting
situation on the date on which threshold was crossed or
reached
|
5.0803%
|
0.0000%
|
5.0803%
|
5,017,091,542
|
||
Position
of previous notification (if
applicable)
|
N/A
|
N/A
|
N/A
|
|
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reachedviii
|
|||||||||
A: Voting rights attached to shares
|
|||||||||
Class/type ofshares
ISIN
code (if possible)
|
Number of voting rightsix
|
% of voting rights
|
|||||||
Direct
(Art 9
of Directive 2004/109/EC) (DTR5.1)
|
Indirect
(Art 10
of Directive 2004/109/EC) (DTR5.2.1)
|
Direct
(Art 9
of Directive 2004/109/EC) (DTR5.1)
|
Indirect
(Art 10
of Directive 2004/109/EC) (DTR5.2.1)
|
||||||
Ordinary
Shares (GB0009252882)
|
|
208,357,778
|
|
4.1530%
|
|||||
ADRs
(US37733W1053)
|
|
46,524,658
|
|
0.9273%
|
|||||
|
|
|
|
|
|||||
SUBTOTAL 8. A
|
254,882,436
|
5.0803%
|
|||||||
|
|||||||||
B 1: Financial Instruments according to Art. 13(1)(a) of Directive
2004/109/EC (DTR5.3.1.1 (a))
|
|||||||||
Type of financial instrument
|
Expirationdatex
|
Exercise/ Conversion Periodxi
|
Number of voting rights that may be acquired if the instrument
is
exercised/converted.
|
% of voting rights
|
|||||
N/A
|
|
|
|
|
|||||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
|
|
SUBTOTAL 8. B 1
|
|
|
|||||
|
|||||||||
B 2: Financial Instruments with similar economic effect according
to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1
(b))
|
|||||||||
Type of financial instrument
|
Expirationdatex
|
Exercise/ Conversion Period xi
|
Physical or cash
settlementxii
|
Number of voting rights
|
% of voting rights
|
||||
N/A
|
|
|
|
|
|
||||
|
|
|
|
|
|
||||
|
|
|
|
|
|
||||
|
|
|
SUBTOTAL 8.B.2
|
|
|
9. Information in relation to the person subject to the
notification obligation (please mark the applicable box with
an “X”)
|
||||
Person
subject to the notification obligation is not controlled by any
natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuerxiii
|
|
|||
Full
chain of controlled undertakings through which the voting rights
and/or thefinancial instruments are effectively held starting with
the ultimate controlling natural person or legal entityxiv (please add additional rows as
necessary)
|
X
|
|||
Namexv
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
The Capital Group Companies, Inc.
Holdings
by CG Management companies are set out below:
|
5.0803%
|
0.0000%
|
5.0803%
|
|
● Capital Bank & Trust Company2
|
|
|
|
|
● Capital International, Inc.1
|
|
|
|
|
● Capital International Limited1
|
|
|
|
|
● Capital International Sàrl1
|
|
|
|
|
● Capital Research and Management Company2
|
5.0551%
|
0.0000%
|
5.0551%
|
|
1Indirect subsidiaries of Capital Research and Management
Company.
2Subsidiary of The Capital Group Companies,
Inc.
|
||||
10. In case of proxy voting, please identify:
|
||||
Name of
the proxy holder
|
|
|||
The
number and % of voting rights held
|
|
|||
The
date until which the voting rights will be held
|
|
|||
|
||||
11. Additional informationxvi
|
||||
The
Capital Group Companies, Inc. (“CGC”) is the parent
company of Capital Research and Management Company
(“CRMC”) and Capital Bank & Trust Company
(“CB&T”). CRMC is a U.S.-based investment
management company that serves as investment manager to the
American Funds family of mutual funds, other pooled investment
vehicles, as well as individual and institutional clients.
CRMC and its investment manager affiliates manage equity assets for
various investment companies through three divisions, Capital
Research Global Investors, Capital International Investors and
Capital World Investors. CRMC is the parent company of
Capital Group International, Inc. (“CGII”), which in
turn is the parent company of four investment management companies
(“CGII management companies”): Capital International,
Inc., Capital International Limited, Capital International
Sàrl and Capital International K.K. CGII management
companies and CB&T primarily serve as investment managers to
institutional and high net worth clients. CB&T is a
U.S.-based investment management company that is a registered
investment adviser and an affiliated federally chartered
bank.
Neither
CGC nor any of its affiliates own shares of your company for its
own account. Rather, the shares reported on this Notification
are owned by accounts under the discretionary investment management
of one or more of the investment management companies described
above.
|
Place of completion
|
Los
Angeles, CA, USA
|
Date of completion
|
14 May
2020
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: May
19, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|